Specific diagnostic markers are the key to effective diagnosis and treatment of inborn errors of metabolism (IEM). Untargeted metabolomics allows for the identification of potential novel diagnostic biomarkers. Current separation techniques coupled to high-resolution mass spectrometry provide a powerful tool for structural elucidation of unknown compounds in complex biological matrices. This is a proof-of-concept study testing this methodology to determine the molecular structure of as yet uncharacterized m/z signals that were significantly increased in plasma samples from patients with phenylketonuria and 3-hydroxy-3-methylglutaryl-CoA lyase deficiency. A hybrid linear ion trap-orbitrap high resolution mass spectrometer, capable of multistage fragmentation, was used to acquire accurate masses and product ion spectra of the uncharacterized m/z signals. In order to determine the molecular structures, spectral databases were searched and fragmentation prediction software was used. This approach enabled structural elucidation of novel compounds potentially useful as biomarkers in diagnostics and follow-up of IEM patients. Two new conjugates, glutamyl-glutamyl-phenylalanine and phenylalanine-hexose, were identified in plasma of phenylketonuria patients. These novel markers showed high inter-patient variation and did not correlate to phenylalanine levels, illustrating their potential added value for follow-up. As novel biomarkers for 3-hydroxy-3-methylglutaryl-CoA lyase deficiency, three positional isomers of 3-methylglutaconyl carnitine could be detected in patient plasma. Our results highlight the applicability of current accurate mass multistage fragmentation techniques for structural elucidation of unknown metabolites in human biofluids, offering an unprecedented opportunity to gain further biochemical insights in known inborn errors of metabolism by enabling high confidence identification of novel biomarkers.

Department of Gastroenterology Radboud University Medical Centre Geert Grooteplein 10 6525 GA Nijmegen the Netherlands

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacký University and University Hospital in Olomouc Hněvotínská 5 775 15 Olomouc Czech Republic

Laboratory of Inherited Metabolic Disorders Department of Clinical Chemistry University Hospital in Olomouc 1 P Pavlova 6 775 20 Olomouc Czech Republic

Translational Metabolic Laboratory 830 TML Department of Laboratory Medicine Radboud University Medical Centre Geert Grooteplein 10 6525 GA Nijmegen the Netherlands

Zobrazit více v PubMed

Clin Chem. 2001 Nov;47(11):1945-55 PubMed

Chem Soc Rev. 2011 Jan;40(1):387-426 PubMed

Trends Analyt Chem. 2015 Jun 1;69:52-61 PubMed

Neuropsychology. 2017 May;31(4):437-447 PubMed

Eur J Biochem. 1975 May 6;53(2):581-90 PubMed

Anal Chem. 2013 Mar 19;85(6):3401-8 PubMed

Clin Chim Acta. 1979 Jun 15;94(3):237-40 PubMed

J Biomol Tech. 2008 Sep;19(4):258-66 PubMed

Anal Chem. 2006 Feb 1;78(3):779-87 PubMed

Nucleic Acids Res. 2013 Jan;41(Database issue):D801-7 PubMed

J Inherit Metab Dis. 2015 Nov;38(6):1029-39 PubMed

Clin Chim Acta. 1994 Oct 14;230(1):1-8 PubMed

Anal Chem. 2016 Dec 6;88(23 ):11429-11435 PubMed

Mol Cell Proteomics. 2005 Dec;4(12):2010-21 PubMed

Nat Genet. 2016 Jul;48(7):777-84 PubMed

Proc Natl Acad Sci U S A. 2015 May 26;112(21):6601-6 PubMed

Neuropsychology. 2017 Mar;31(3):242-254 PubMed

Bioanal Rev. 2010 Dec;2(1-4):23-60 PubMed

Metabolomics. 2007 Sep;3(3):211-221 PubMed

A newborn screening approach to diagnose 3-hydroxy-3-methylglutaryl-CoA lyase deficiency

Cellwise outlier detection and biomarker identification in metabolomics based on pairwise log ratios